TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC
Thoracic Cancer · 2026
DOI: 10.1111/1759-7714.70375 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thoracic Cancer, 2026. Verfasst von Zhiqi Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy, Lung Neoplasms, Immunotherapy. Die Arbeit nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes, Beijing Traditional Chinese Medicine Science and Technology Development Fund Project, The Research Project of Inner Mongolia Medical University Affiliated Hospital.
Abstract (Originalsprache)
Tertiary lymphoid structures (TLS) have emerged as critical modulators of antitumor immunity in non‐small cell lung cancer (NSCLC), with growing evidence supporting their role as both prognostic biomarkers and functional targets in neoadjuvant chemoimmunotherapy. TLS are organized ectopic lymphoid aggregates that facilitate local antigen presentation, T and B cell activation, and memory immune responses within the tumor microenvironment. Their presence and maturation status correlate with favorable clinical outcomes and enhanced responsiveness to immune checkpoint inhibitors. Despite these insights, several obstacles hinder clinical translation. Current approaches remain limited in dynamically monitoring TLS evolution during treatment, and the underlying immunoregulatory mechanisms—particularly interactions among immune subsets, stromal components, and tumor cells—are not fully elucidated. Additionally, translation faces challenges including inter‐institutional variability, lack of standardized assessment criteria, and the need for multi‐center prospective validation. Integrating multimodal technologies—high‐plex imaging, spatial transcriptomics, and digital pathology—with AI‐based platforms holds promise for refined TLS characterization and real‐time monitoring. Near‐term priorities include optimizing dynamic monitoring techniques and establishing standardized scoring systems. Medium‐to‐long‐term priorities encompass multi‐center trials to validate TLS utility across diverse populations, identify novel drivers of TLS formation, and develop optimized combinatorial immunotherapy regimens that leverage TLS as both predictive biomarkers and therapeutic targets. By bridging basic immunology and clinical oncology, TLS are poised to emerge as key regulatory nodes in precision cancer immunotherapy, which may catalyze a paradigm shift in the neoadjuvant NSCLC landscape, enabling a closed‐loop management framework encompassing prediction, intervention, and dynamic efficacy optimization across the entire continuum of patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
- Department of Pathology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
- School of Continuing Education, Beijing University of Chinese Medicine, Beijing, China.
ORCID-Profile: Ling Yi, Yuanming Pan
Förderung
- Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes
- Beijing Traditional Chinese Medicine Science and Technology Development Fund Project
- The Research Project of Inner Mongolia Medical University Affiliated Hospital
- Beijing Municipal Administration of Hospital Incubating Program
- The Capability Program of Beijing Tuberculosis & Thoracic Tumor Research Institute
Zitieren
APA
Li, Z., Zhang, L., Dong, Y., Yi, L., Li, W., Wang, J., & Pan, Y. (2026). TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70375
Vancouver
Li Z, Zhang L, Dong Y, Yi L, Li W, Wang J, et al. TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC. Thoracic Cancer. 2026. doi:10.1111/1759-7714.70375
BibTeX
@article{Li2026,
author = {Li, Zhiqi and Zhang, Lina and Dong, Yujie and Yi, Ling and Li, Weiying and Wang, Jinghui and Pan, Yuanming},
title = {TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC},
journal = {Thoracic Cancer},
year = {2026},
doi = {10.1111/1759-7714.70375}
}
EUVIMED